Serum vascular endothelial growth factor B is elevated in women with polycystic ovary syndrome and can be decreased with metformin treatment

Clinical Endocrinology

Volumn 84, Issue 3, 2016, Pages 386-393

  Cheng, Feifei ^a   Zhao, Lu ^a   Wu, Yuanyuan ^a   Huang, Tiantian ^a   Yang, Gangyi ^a   Zhang, Zhanyu ^a   Wu, Yijia ^a   Jia, Fang ^a   Wu, Jinlin ^b   Chen, Chen ^c   Liu, Dongfang ^a  

^a THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b CHONGQING TRADITIONAL CHINESE MEDICINE HOSPITAL   (China)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; METFORMIN; VASCULOTROPIN B; ANTIDIABETIC AGENT; LIPID; SEX HORMONE;

ADULT; ARTICLE; BODY FAT; BODY MASS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; HUMAN CELL; INSULIN RESISTANCE; INTERVENTION STUDY; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; OBESITY; OVARY POLYCYSTIC DISEASE; PANCREAS INSUFFICIENCY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; BLOOD; POLYCYSTIC OVARY SYNDROME; STATISTICAL MODEL; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; FEMALE; GONADAL STEROID HORMONES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LINEAR MODELS; LIPIDS; METFORMIN; OBESITY; OVERWEIGHT; POLYCYSTIC OVARY SYNDROME; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR B; YOUNG ADULT;

EID: 84958887308     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12950     Document Type: Article

References (31)

1. Olsson, A.K., Dimberg, A., Kreuger, J., et al,. (2006) VEGF receptor signalling-in control of vascular function. Nature Reviews Molecular Cell Biology, 7, 359-371.
2. Hagberg, C.E., Mehlem, A., Falkevall, A., et al,. (2012) Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. Nature, 490, 426-430.
3. Lu, X., Ji, Y., Zhang, L., et al,. (2012) Resistance to obesity by repression of VEGF gene expression through induction of brown-like adipocyte differentiation. Endocrinology, 153, 3123-3132.
4. Hagberg, C.E., Falkevall, A., Wang, X., et al,. (2010) Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature, 464, 917-921.
5. Dewailly, D., Cortet-Rudelli, C., Nobels, F., et al,. (1992) Insulin resistance and polycystic ovary syndrome. Annales d'Endocrinologie, 53, 1-7.
6. Gomez-Ambrosi, J., Catalan, V., Rodriguez, A., et al,. (2010) Involvement of serum vascular endothelial growth factor family members in the development of obesity in mice and humans. The Journal of Nutritional Biochemistry, 21, 774-780.
7. Gomez-Ambrosi, J., Catalan, V., Diez-Caballero, A., et al,. (2004) Gene expression profile of omental adipose tissue in human obesity. FASEB Journal, 18, 215-217.
8. Sun, C.Y., Lee, C.C., Hsieh, M.F., et al,. (2014) Clinical association of circulating VEGF-B levels with hyperlipidemia and target organ damage in type 2 diabetic patients. Journal of Biological Regulators and Homeostatic Agents, 28, 225-236.
9. Palomba, S., Falbo, A., Zullo, F., et al,. (2009) Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocrine Reviews, 30, 1-50.
10. Romualdi, D., De Cicco, S., Gagliano, D., et al,. (2013) How metformin acts in PCOS pregnant women: insights into insulin secretion and peripheral action at each trimester of gestation. Diabetes Care, 36, 1477-1482.
11. Genazzani, A.D., Strucchi, C., Luisi, M., et al,. (2006) Metformin administration modulates neurosteroids secretion in non-obese amenorrhoic patients with polycystic ovary syndrome. Gynecological Endocrinology, 22, 36-43.
12. Spritzer, P.M., (2014) Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances. Arquivos Brasileiros de Endocrinologia & Metabologia, 58, 182-187.
13. Bogachus, L.D., &, Turcotte, L.P., (2010) Genetic downregulation of AMPK-alpha isoforms uncovers the mechanism by which metformin decreases FA uptake and oxidation in skeletal muscle cells. American Journal of Physiology Cell Physiology, 299, C1549-C1561.
14. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction (Oxford, England), 19, 41-47.
15. Steering Committee of the Western Pacific Region of the World Health Organization tIOTF. The Asia-Pacific perspective: Redefining Obesity and its Treatment. Health Communications Australia Pty Limited, Melbourne, 2000. 2000.
16. Lee, H., Oh, J.Y., Sung, Y.A., et al,. (2009) The prevalence and risk factors for glucose intolerance in young Korean women with polycystic ovary syndrome. Endocrine, 36, 326-332.
17. Hojlund, K., Glintborg, D., Andersen, N.R., et al,. (2008) Impaired insulin-stimulated phosphorylation of Akt and AS160 in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment. Diabetes, 57, 357-366.
18. Hutchison, S.K., Stepto, N.K., Harrison, C.L., et al,. (2011) Effects of exercise on insulin resistance and body composition in overweight and obese women with and without polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism, 96, E48-E56.
19. Wu, J., Wu, Y., Zhang, X., et al,. (2014) Elevated serum thioredoxin-interacting protein in women with polycystic ovary syndrome is associated with insulin resistance. Clinical Endocrinology, 80, 538-544.
20. DeFronzo, R.A., Tobin, J.D., &, Andres, R., (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. The American Journal of Physiology, 237, E214-E223.
21. Haffner, S.M., Valdez, R.A., Hazuda, H.P., et al,. (1992) Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes, 41, 715-722.
22. Cobelli, C., Toffolo, G.M., Dalla Man, C., et al,. (2007) Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. American Journal of Physiology Endocrinology and Metabolism, 293, E1-E15.
23. Utzschneider, K.M., Prigeon, R.L., Faulenbach, M.V., et al,. (2009) Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care, 32, 335-341.
24. Stumvoll, M., Van Haeften, T., Fritsche, A., et al,. (2001) Oral glucose tolerance test indexes for insulin sensitivity and secretion based on various availabilities of sampling times. Diabetes Care, 24, 796-797.
25. Stancakova, A., Javorsky, M., Kuulasmaa, T., et al,. (2009) Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6414 Finnish men. Diabetes, 58, 1212-1221.
26. Matsuda, M., &, DeFronzo, R.A., (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care, 22, 1462-1470.
27. Samuel, V.T., Petersen, K.F., &, Shulman, G.I., (2010) Lipid-induced insulin resistance: unravelling the mechanism. Lancet, 375, 2267-2277.
28. Perseghin, G., Scifo, P., De Cobelli, F., et al,. (1999) Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes, 48, 1600-1606.
29. Kim, Y.D., Park, K.G., Lee, Y.S., et al,. (2008) Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes, 57, 306-314.
30. Zhou, G., Myers, R., Li, Y., et al,. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. The Journal of Clinical Investigation, 108, 1167-1174.
31. Banaszewska, B., Duleba, A.J., Spaczynski, R.Z., et al,. (2006) Lipids in polycystic ovary syndrome: role of hyperinsulinemia and effects of metformin. American Journal of Obstetrics and Gynecology, 194, 1266-1272.